Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Hold" by Analysts

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given an average recommendation of "Hold" by the eight brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $5.43.

A number of research analysts recently weighed in on AKYA shares. Piper Sandler reaffirmed an "overweight" rating and set a $3.00 price objective (down previously from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Craig Hallum lowered Akoya Biosciences from a "buy" rating to a "hold" rating and reduced their target price for the stock from $7.00 to $5.00 in a report on Friday, November 15th. Finally, Canaccord Genuity Group reduced their target price on Akoya Biosciences from $6.00 to $3.50 and set a "buy" rating for the company in a report on Friday, November 15th.

Akoya Biosciences Stock Down 5.5 %

AKYA stock traded down $0.12 on Thursday, reaching $2.07. 62,013 shares of the company traded hands, compared to its average volume of 220,964. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85. The company has a market cap of $102.59 million, a P/E ratio of -1.75 and a beta of 1.22. The firm has a fifty day simple moving average of $2.74 and a 200-day simple moving average of $2.49.

Institutional Trading of Akoya Biosciences

Several large investors have recently modified their holdings of AKYA. Vanguard Group Inc. grew its holdings in shares of Akoya Biosciences by 3.3% in the first quarter. Vanguard Group Inc. now owns 1,454,288 shares of the company's stock worth $6,821,000 after acquiring an additional 46,131 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Akoya Biosciences by 16.2% in the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company's stock worth $158,000 after acquiring an additional 9,429 shares during the period. Regal Investment Advisors LLC grew its holdings in shares of Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company's stock worth $44,000 after acquiring an additional 7,340 shares during the period. GSA Capital Partners LLP grew its holdings in shares of Akoya Biosciences by 87.4% in the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company's stock worth $845,000 after acquiring an additional 144,903 shares during the period. Finally, State Street Corp grew its holdings in shares of Akoya Biosciences by 4.2% in the third quarter. State Street Corp now owns 453,296 shares of the company's stock worth $1,233,000 after acquiring an additional 18,361 shares during the period. Institutional investors own 79.42% of the company's stock.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.